Examkin

All practice questions

4736 questions

All types4,736Multiple choice2,413Multiple select567Numeric127Matching858Ordering771
Question 3281Question →

During an outpatient rheumatology consultation, a 47-year-old female patient is diagnosed with seropositive rheumatoid arthritis following a four-month history of bilateral symmetric swelling in her proximal interphalangeal and metacarpophalangeal joints. The physician and patient engage in shared decision-making and agree to initiate systemic disease-modifying antirheumatic drug (DMARD) therapy with weekly oral methotrexate. The patient has a history of mild essential hypertension and takes amlodipine. Which of the following baseline evaluations are necessary to safely initiate and subsequently monitor this specific pharmacotherapy? (Select the three that apply)

Select all that apply

Show answer & explanation

Answer: Complete blood count; Serum aminotransferases; Serum creatinine

Answer

The correct baseline and ongoing evaluations for methotrexate therapy are a complete blood count, serum aminotransferases, and serum creatinine.
Methotrexate is a folate antimetabolite and the preferred initial disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. Because of its toxicity profile, stringent baseline and ongoing laboratory monitoring are required. Methotrexate is primarily excreted by the kidneys; therefore, a baseline serum creatinine is essential to identify renal impairment, which increases the risk of severe toxicity and may require dose adjustment or represent a contraindication. Additionally, methotrexate carries risks of hepatotoxicity and dose-dependent bone marrow suppression. Consequently, baseline and periodic monitoring of serum aminotransferases (to detect liver injury) and a complete blood count (to monitor for myelosuppression, including leukopenia, anemia, and thrombocytopenia) are mandatory.

Step-by-Step Solution

1
Identify the initiated medication and its indication
The patient is starting methotrexate for moderate-to-severe rheumatoid arthritis.
Different DMARDs have unique toxicity profiles that dictate necessary baseline testing.
2
Recall the major toxicities and excretion pathways of the medication
Methotrexate can cause myelosuppression and hepatotoxicity, and it is renally excreted.
Monitoring parameters are directly linked to preventing or detecting these specific adverse effects.
3
Select the laboratory tests that monitor these specific systems
Complete blood count, serum aminotransferases, and serum creatinine are identified as the necessary tests.
These tests ensure the drug can be safely cleared and check for its primary organ toxicities.

Key Concept

Methotrexate requires baseline and ongoing monitoring of renal function (serum creatinine), hepatic function (serum aminotransferases), and bone marrow function (complete blood count) due to its clearance mechanism and toxicity profile.
Question 3282Question →

A 60-year-old male is evaluated in the surgical critical care unit due to rapidly worsening groin pain and hemodynamic instability. He was admitted earlier today with a presumed diagnosis of severe scrotal cellulitis. His past medical history includes long-standing, insulin-dependent diabetes mellitus. Current vital signs include a temperature of 39.1°C (102.4°F), heart rate of 128/min, blood pressure of 82/50 mm Hg, and respiratory rate of 26/min. The patient is lethargic but moans during the examination. The genitourinary exam reveals induration, violaceous discoloration, and palpable crepitus extending from the perineum into the lower anterior abdominal wall. A foul-smelling, dishwater-like fluid is seeping from a small ulceration on the scrotum. Broad-spectrum intravenous antibiotics and aggressive fluid resuscitation are currently being administered. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Immediate transfer to the operating room for radical surgical debridement

Answer

Immediate transfer to the operating room for radical surgical debridement
The correct answer is immediate transfer to the operating room for radical surgical debridement. The patient's presentation—rapidly progressive perineal pain, crepitus, violaceous skin discoloration, dishwater-like discharge, and concurrent septic shock—is the classic clinical picture of necrotizing fasciitis (specifically Fournier gangrene when involving the perineum). Necrotizing fasciitis is a surgical emergency. The infection spreads rapidly along deep fascial planes where thrombosis of nutrient vessels causes tissue ischemia, limiting the delivery of intravenous antibiotics. Therefore, definitive management requires emergent surgical exploration and aggressive debridement of all devitalized tissue. Delaying surgery significantly increases mortality.

Step-by-Step Solution

1
Evaluate the patient's clinical presentation and vital signs.
The patient exhibits systemic toxicity, septic shock (hypotension, tachycardia), and localized signs of a severe soft tissue infection including crepitus and dishwater drainage.
To differentiate between uncomplicated cellulitis and a necrotizing soft tissue infection.
2
Diagnose the underlying condition.
The presence of crepitus, pain out of proportion to early visible skin changes, and rapidly spreading necrosis in a diabetic patient strongly indicates necrotizing fasciitis (Fournier gangrene).
Clinical diagnosis of necrotizing fasciitis dictates immediate management priorities.
3
Determine the necessary intervention.
The patient requires emergent surgical source control to halt the spread of infection along fascial planes.
Antibiotics and fluid resuscitation alone are insufficient; survival depends on the rapid physical removal of devitalized tissue.

Key Concept

Emergent surgical debridement is the primary and most critical intervention for necrotizing fasciitis; it must not be delayed for imaging when the clinical picture is clear.
Question 3283Question →

A 22-year-old man with type 1 diabetes mellitus is managed in the intensive care unit for diabetic ketoacidosis (DKA). He has been receiving a continuous intravenous regular insulin infusion, appropriate intravenous fluids, and potassium supplementation for the past 1414 hours. The most recent basic metabolic panel reveals a blood glucose of 185185 mg/dL, a serum bicarbonate of 1919 mEq/L, and a calculated anion gap of 1010 mEq/L. The patient is awake, alert, and states he is hungry. The physician decides to transition the patient from intravenous to subcutaneous insulin therapy. Arrange the following steps in the most appropriate chronological order to safely accomplish this therapeutic transition and ongoing monitoring.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for transitioning a patient from intravenous to subcutaneous insulin after DKA resolution is: 1) Document DKA resolution and oral tolerance, 2) Administer subcutaneous insulin, 3) Continue IV insulin for a 1-2 hour overlap, 4) Stop IV insulin, 5) Begin routine pre-meal and bedtime blood glucose monitoring.
The correct sequence follows guideline-directed de-escalation of DKA management. First, criteria for resolution must be met (glucose < 200200 mg/dL, bicarbonate \geq 1818 mEq/L, and calculated anion gap \leq 1212 mEq/L) and the patient must tolerate oral intake. Next, subcutaneous insulin (both basal and prandial) is administered. Crucially, the intravenous regular insulin infusion must be continued for 11 to 22 hours after the subcutaneous injection. This overlap is required because intravenous insulin has a half-life of less than 1010 minutes, whereas subcutaneous insulin takes 11 to 22 hours to achieve significant systemic absorption. Stopping the IV infusion prematurely leads to a lapse in circulating insulin and rebound ketoacidosis. Once the overlap period concludes, the IV infusion is stopped, and the patient is placed on routine blood glucose monitoring to evaluate the new regimen.

Step-by-Step Solution

1
Confirm clinical and biochemical resolution
Anion gap is closed (\leq 1212 mEq/L) and patient can eat.
Ensures the patient is physiologically ready for therapeutic de-escalation.
2
Administer subcutaneous insulin
Patient receives basal and prandial SQ dose.
Provides the new source of insulin before the old one is removed.
3
Overlap IV and SQ insulin
IV infusion runs concurrently for 11-22 hours post-SQ injection.
Prevents insulin deficiency and rebound DKA while SQ insulin absorbs.
4
Stop IV insulin
Patient is solely on SQ insulin.
Completes the transition once SQ insulin is fully active.
5
Start routine monitoring
Point-of-care glucose checks are scheduled before meals and at bedtime.
Allows evaluation of the new SQ regimen's efficacy and ensures stability.

Key Concept

Multi-step therapeutic de-escalation and monitoring protocol for Diabetic Ketoacidosis (DKA)
Question 3284Question →

A 5656-year-old man visits his primary care provider due to intense pain and swelling in his right great toe that began abruptly overnight. He reports that the pain is so severe he cannot tolerate the weight of a bedsheet on his foot. The patient underwent a deceased-donor kidney transplantation 33 years ago for end-stage renal disease secondary to hypertensive nephrosclerosis. His maintenance immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and prednisone (5 mg5\text{ mg} daily). His other medications include amlodipine and low-dose aspirin. Vital signs show a temperature of 37.3∘C37.3^\circ\text{C} (99.1∘F99.1^\circ\text{F}), blood pressure of 134/82 mmHg134/82\text{ mmHg}, and heart rate of 88/min88/\text{min}. Examination of the right lower extremity reveals marked erythema, edema, and exquisite tenderness localized to the first metatarsophalangeal joint. Recent laboratory testing demonstrates a serum creatinine of 1.6 mg/dL1.6\text{ mg/dL}, which is unchanged from his baseline over the past year. Serum uric acid is 9.2 mg/dL9.2\text{ mg/dL}. An arthrocentesis of the affected joint yields cloudy fluid with a leukocyte count of 32,000/mm332,000/\text{mm}^3 (85%85\% neutrophils). A Gram stain shows no organisms. Polarized light microscopy demonstrates numerous negatively birefringent, needle-shaped crystals. Which of the following is the most appropriate initial pharmacologic intervention for this patient's joint symptoms?

Show answer & explanation

Answer: Intra-articular triamcinolone acetonide

Answer

The most appropriate initial pharmacologic intervention is the administration of an intra-articular glucocorticoid, such as triamcinolone acetonide.
The correct answer utilizes a localized therapy to treat the acute inflammatory gout flare while entirely bypassing the high-risk systemic pharmacokinetics of the patient's transplant regimen. Intra-articular glucocorticoids are highly effective for monoarticular gout and pose no risk of drug-drug interactions with tacrolimus, nor do they compromise the transplanted kidney's hemodynamics.

Step-by-Step Solution

1
Diagnose the patient's acute presentation.
The acute onset of severe monoarticular pain, erythema, and swelling in the first metatarsophalangeal joint (podagra), combined with synovial fluid showing negatively birefringent needle-shaped crystals, confirms an acute gout flare.
Establishing the definitive diagnosis prevents inappropriate interventions, such as treating for presumed septic arthritis based on an elevated synovial leukocyte count alone.
2
Identify the patient's complex medical background and current pharmacological regimen.
The patient is a renal transplant recipient on maintenance immunosuppression, critically including the calcineurin inhibitor tacrolimus.
Standard acute gout therapies carry severe, potentially life-threatening risks when used in the setting of solid organ transplantation and calcineurin inhibitors.
3
Evaluate standard gout therapies against the patient's specific contraindications.
NSAIDs are contraindicated due to the risk of exacerbating tacrolimus-induced afferent arteriole vasoconstriction and causing acute allograft rejection/injury. Colchicine is contraindicated because tacrolimus inhibits its clearance via P-gp and CYP3A4, risking fatal toxicity.
Ruling out unsafe systemic options narrows the choices to localized therapies or alternative systemic agents.
4
Select the safest, most effective intervention.
Intra-articular triamcinolone acetonide.
Since the flare is limited to a single easily accessible joint, a localized glucocorticoid injection provides rapid relief while avoiding systemic drug interactions and nephrotoxicity.

Key Concept

Management of acute gout in solid organ transplant recipients requires avoiding NSAIDs (which worsen calcineurin inhibitor nephrotoxicity) and colchicine (which reaches toxic levels due to calcineurin inhibitor-mediated CYP3A4 and P-gp inhibition); intra-articular glucocorticoids are the preferred safe alternative.
Question 3285Question →

A 31-year-old pregnant woman (G2P1) at 34 weeks gestation arrives at the obstetric triage unit reporting severe right-sided back pain, nausea, and shaking chills over the past 24 hours. Her temperature is 39.1°C (102.4°F), blood pressure is 100/60 mm Hg, pulse is 112/min, and respiratory rate is 20/min. Physical examination reveals pronounced right costovertebral angle tenderness. Fetal heart rate tracing is reassuring, and there are no uterine contractions. Laboratory studies show a leukocyte count of 16,500/mm³. Urinalysis is positive for nitrites, leukocyte esterase, and >50 white blood cells per high-power field. The patient's medical history is notable for a severe anaphylactic reaction characterized by hypotension and wheezing following amoxicillin administration during childhood. Five years ago, she developed a diffuse maculopapular rash and facial swelling after taking cephalexin. Which of the following is the most appropriate empiric pharmacotherapy for this patient?

Show answer & explanation

Answer: Intravenous aztreonam

Answer

Intravenous aztreonam is the most appropriate empiric pharmacotherapy because it provides necessary gram-negative coverage for pyelonephritis, is safe in pregnancy, and will not trigger cross-reactivity in a patient with severe beta-lactam anaphylaxis.
The correct answer is intravenous aztreonam. This patient presents with acute pyelonephritis during the third trimester of pregnancy, a serious infection that requires prompt hospital admission and intravenous antibiotics due to the high risk of maternal sepsis and preterm labor. The standard first-line therapies for pyelonephritis in pregnancy typically include intravenous broad-spectrum beta-lactams, such as ceftriaxone or ampicillin-sulbactam. However, this patient has a history of true, severe IgE-mediated anaphylaxis to amoxicillin (hypotension, wheezing) and a severe reaction to cephalexin (facial swelling/angioedema). Consequently, all penicillins and cephalosporins are absolutely contraindicated. While carbapenems have a low rate of cross-reactivity, they are generally avoided in patients with a history of life-threatening beta-lactam anaphylaxis unless no other options exist. Aztreonam is a monobactam antibiotic that targets gram-negative aerobic bacteria (the primary culprits in pyelonephritis, such as E. coli). Critically, its monocyclic beta-lactam ring structure confers no cross-reactivity with penicillins or cephalosporins (with the sole exception of ceftazidime, which shares an identical side chain). Aztreonam is highly effective for pyelonephritis and has an established safety profile in pregnancy, making it the most appropriate choice.

Step-by-Step Solution

1
Diagnose the acute condition based on the clinical presentation.
The patient has acute pyelonephritis, presenting with fever, flank pain, costovertebral angle tenderness, and a suggestive urinalysis in the third trimester of pregnancy.
Establishing the diagnosis determines the required scope of antimicrobial coverage (primarily enteric gram-negative rods like E. coli) and the need for systemic, tissue-penetrating pharmacokinetics.
2
Determine the appropriate setting and route of administration.
Hospital admission and intravenous antibiotics are required.
Acute pyelonephritis in pregnancy carries a high risk of progression to maternal sepsis, acute respiratory distress syndrome (ARDS), and preterm labor. Rapid systemic stabilization via the IV route is mandatory.
3
Analyze the patient's allergy history to rule out contraindicated classes.
Penicillins, cephalosporins, and carbapenems must be avoided due to the history of IgE-mediated anaphylaxis (hypotension, wheezing, facial swelling).
Administering a beta-lactam with cross-reactivity potential in a patient with documented anaphylaxis risks a fatal hypersensitivity reaction.
4
Select a pharmacologic agent that safely balances antimicrobial efficacy and fetal safety.
Aztreonam is selected.
Aztreonam, a monobactam, provides isolated gram-negative coverage suitable for pyelonephritis, has no structural cross-reactivity with penicillins/cephalosporins (except ceftazidime), and is safe during pregnancy, unlike fluoroquinolones or aminoglycosides.

Key Concept

Empiric antimicrobial selection in pregnant patients with severe beta-lactam allergy
Question 3286Question →

A 28-year-old primigravid patient at 28 weeks of gestation presents for a scheduled prenatal evaluation. Her pregnancy has been uncomplicated thus far. She reports normal fetal movement and denies any vaginal bleeding, leakage of fluid, or contractions. Her pre-pregnancy body mass index was 23 kg/m^2, and her weight gain has been appropriate. Her blood pressure is 110/70 mmHg. Routine laboratory results from her first-trimester evaluation, including HIV, rapid plasma reagin, and hepatitis B surface antigen tests, were negative. Her last Papanicolaou test was performed two years ago and was reported as normal. She has no acute symptoms today. Which of the following preventive care interventions are currently indicated for this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Administration of the tetanus, diphtheria, and acellular pertussis vaccine; Screening for gestational diabetes mellitus with an oral glucose tolerance test

Answer

The indicated preventive interventions are the administration of the tetanus, diphtheria, and acellular pertussis vaccine and screening for gestational diabetes mellitus.
The correct preventive interventions for a patient at 28 weeks of gestation include the administration of the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine and screening for gestational diabetes mellitus. The Advisory Committee on Immunization Practices (ACIP) recommends the Tdap vaccine during every pregnancy, optimally between 27 and 36 weeks of gestation, to provide passive immunity to the infant against pertussis. The US Preventive Services Task Force (USPSTF) recommends screening for gestational diabetes in asymptomatic pregnant persons at 24 to 28 weeks of gestation.

Step-by-Step Solution

1
Determine the patient's current gestational age and relevant medical history.
The patient is a 28-year-old primigravida at 28 weeks of gestation with an uncomplicated pregnancy and up-to-date prior screenings.
Preventive guidelines during pregnancy are strictly dependent on the specific trimester and gestational week.
2
Identify the recommended immunizations for the late second to early third trimester.
The tetanus, diphtheria, and acellular pertussis (Tdap) vaccine is indicated.
Guidelines recommend Tdap vaccination during every pregnancy, optimally between 27 and 36 weeks, regardless of prior vaccination history.
3
Identify the recommended disease screenings for the late second to early third trimester.
Screening for gestational diabetes mellitus is indicated.
Routine screening for gestational diabetes is performed between 24 and 28 weeks of gestation in asymptomatic patients.
4
Evaluate the distractors based on the patient's age and gestational timeline.
Asymptomatic bacteriuria screening is past due, the human papillomavirus vaccine is contraindicated, and cervical cytology is not yet due.
To ensure that unnecessary or contraindicated interventions are not inappropriately ordered.

Key Concept

Routine preventive care during pregnancy includes administering the Tdap vaccine between 27 and 36 weeks of gestation and screening for gestational diabetes mellitus between 24 and 28 weeks of gestation.
Question 3287Question →

A physician evaluates a 41-year-old female patient who schedules a visit to establish care and discuss her long-term health maintenance. She reports feeling perfectly well and has no physical complaints. Her medical history is unremarkable, and she takes no prescription medications. The patient's family history is significant for a maternal aunt diagnosed with melanoma at age 60; there is no family history of breast, colon, or gynecologic malignancies. She does not use tobacco products and consumes one glass of wine per week. Her blood pressure is 115/72 mmHg, and her body mass index is 22 kg/m². A review of her outside medical records indicates that her last cervical cancer screening, which utilized primary human papillomavirus (HPV) testing, was performed three years ago at age 38 and returned negative results. Based on current guidelines, which of the following screening tests should be recommended for this patient today?

Show answer & explanation

Answer: Screening mammography

Answer

Screening mammography is the correct and most appropriate preventive intervention for this patient today.
The correct answer is screening mammography because the United States Preventive Services Task Force (USPSTF) recommends that all average-risk women undergo biennial screening mammography starting at age 40 and continuing through age 74. Because this patient is 41 years old and has not yet established a screening regimen, initiating breast cancer screening is the most appropriate guideline-concordant next step in her preventive care.

Step-by-Step Solution

1
Evaluate the patient's age and baseline risk profile.
The patient is a 41-year-old female with a normal BMI, no tobacco use, and no high-risk family history for major malignancies.
Risk factors and age strictly dictate the initiation and frequency of preventive screenings.
2
Assess eligibility for breast cancer screening.
Recent updates to guidelines mandate that average-risk women begin biennial screening mammography at age 40.
This patient is 41, making her eligible and currently due for her initial screening mammogram.
3
Review the patient's prior screening history for cervical cancer.
The patient had negative primary HPV testing three years ago. The appropriate interval is every 5 years, meaning she is not due today.
Adhering to correct screening intervals prevents over-testing and unnecessary healthcare costs.
4
Rule out other common screenings based on demographic criteria.
Colorectal screening (starts at 45) and diabetes screening (requires overweight/obesity) are ruled out.
The patient does not meet the minimum age or BMI thresholds for these tests.

Key Concept

Average-risk women should begin biennial screening mammography for breast cancer at age 40.
Estimated Time:1m 0s
Question 3288Question →

A 64-year-old woman comes to the primary care clinic for a routine follow-up. Six months ago, she was diagnosed with symptomatic paroxysmal atrial fibrillation and was subsequently started on oral amiodarone. She reports that her palpitations have completely resolved and she has been able to resume her daily 2-mile walks without shortness of breath, fatigue, or cough. Her other medical history is unremarkable. Current medications include amiodarone and apixaban. Vital signs are within normal limits. Physical examination shows a regular rate and rhythm with no murmurs, and clear lungs bilaterally. Which of the following diagnostic tests are indicated for the routine ongoing monitoring of this patient's antiarrhythmic therapy? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Serum aminotransferases; Serum thyroid-stimulating hormone

Answer

Serum aminotransferases and Serum thyroid-stimulating hormone
Amiodarone is an iodine-rich class III antiarrhythmic agent associated with several long-term tissue toxicities, most notably involving the thyroid, liver, and lungs. Routine monitoring is essential to detect early asymptomatic dysfunction. Current guidelines strictly recommend checking serum aminotransferases (AST and ALT) and a serum thyroid-stimulating hormone (TSH) level at baseline and every 6 months during therapy. Hepatic toxicity is typically asymptomatic but can progress to cirrhosis if unmonitored. Thyroid dysfunction can manifest as either amiodarone-induced hypothyroidism (more common) or thyrotoxicosis.

Step-by-Step Solution

1
Identify the primary medications the patient is taking and their associated indications.
The patient is taking amiodarone for paroxysmal atrial fibrillation and apixaban for stroke prophylaxis.
Establishes the pharmacologic targets for ongoing monitoring.
2
Recall the specific organ toxicities associated with chronic amiodarone therapy.
Amiodarone causes pulmonary, thyroid, hepatic, ophthalmic, and dermatologic toxicities.
Narrows down the potential laboratory and clinical monitoring requirements to the affected organ systems.
3
Determine the guideline-recommended timeline for amiodarone monitoring.
Guidelines recommend checking liver function tests (aminotransferases) and thyroid function (TSH) at baseline and every 6 months.
Selects the precise laboratory tests appropriate for a 6-month asymptomatic follow-up.
4
Evaluate the need for monitoring the patient's anticoagulant.
The patient is on apixaban. While amiodarone strongly interacts with warfarin (requiring INR monitoring), apixaban does not require routine coagulation monitoring.
Eliminates PT/INR from the required monitoring checklist.

Key Concept

Chronic amiodarone therapy requires routine monitoring of thyroid function (TSH) and hepatic function (aminotransferases) at baseline and every 6 months due to the risk of asymptomatic organ toxicity.
Question 3289Question →

A 46-year-old female presents to the primary care clinic for a routine health maintenance evaluation. She has a history of seropositive rheumatoid arthritis, which was diagnosed 4 years ago. Her disease is currently well controlled on a regimen of weekly methotrexate and subcutaneous etanercept. She feels well and reports no joint pain, stiffness, or systemic symptoms. She smoked one pack of cigarettes daily for 15 years but quit 5 years ago. She has no other chronic medical conditions, and her only other medication is a daily multivitamin. Her most recent screening tests include a normal colonoscopy at age 45 and a normal screening mammogram 8 months ago. Hepatitis B and C virus screening tests were negative 3 years ago. She received a tetanus-diphtheria-pertussis (Tdap) booster 4 years ago. She has not yet received an influenza vaccine this season. Vital signs are within normal limits, and physical examination is unremarkable. Which of the following is the most appropriate next step in preventive care for this patient?

Show answer & explanation

Answer: Administration of the 20-valent pneumococcal conjugate vaccine

Answer

The most appropriate next step is the administration of the 20-valent pneumococcal conjugate vaccine because the patient is immunocompromised from her rheumatoid arthritis medications.
This patient requires pneumococcal vaccination due to iatrogenic immunosuppression. According to the Advisory Committee on Immunization Practices (ACIP), adults aged 19 through 49 years who have an immunocompromising condition—such as taking immunosuppressive medications (e.g., methotrexate, TNF inhibitors like etanercept)—should receive pneumococcal vaccination. The recommended approach is a single dose of the 20-valent pneumococcal conjugate vaccine (PCV20), or alternatively, the 15-valent pneumococcal conjugate vaccine (PCV15) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Additionally, she should receive the seasonal influenza vaccine, but it must be the inactivated formulation.

Step-by-Step Solution

1
Analyze the patient's demographic and clinical risk profile.
The patient is a 46-year-old female on immunosuppressive therapy (methotrexate and etanercept) for rheumatoid arthritis.
Identifying iatrogenic immunosuppression is critical for determining appropriate vaccine indications and contraindications.
2
Evaluate indicated vaccinations based on the patient's risk profile.
Because of her immunosuppression, she requires pneumococcal vaccination despite being under the universal age guideline of 50 years.
ACIP guidelines recommend pneumococcal vaccination for adults aged 19-49 with an immunocompromising condition.
3
Evaluate the distractors for contraindications or lack of indication.
Live-attenuated influenza vaccine is contraindicated. She does not meet criteria for lung cancer screening, and routine ECG or pelvic ultrasound are not recommended.
Preventive care requires avoiding unnecessary testing and avoiding harm from contraindicated interventions.

Key Concept

Adults aged 19 to 49 years with an immunocompromising condition (including use of immunosuppressive medications) should receive pneumococcal vaccination (e.g., a single dose of PCV20).
Question 3290Question →

An independent 68-year-old woman visits the clinic to establish care and discuss her health maintenance. Her past medical history includes well-controlled essential hypertension and primary hypothyroidism. She consumed one pack of cigarettes daily for 25 years but successfully abstained from tobacco starting 12 years ago. Family history is notable for her mother passing away from ovarian cancer at age 72. Review of her medical records reveals a normal colonoscopy at age 64, a normal bilateral mammogram 11 months ago, and negative cervical cytology with negative high-risk HPV testing at age 63. She has documented consecutive negative cervical cancer screenings over the preceding two decades. A bone mineral density evaluation performed at age 65 demonstrated a T-score of -0.4 at the lumbar spine. Which of the following is the most appropriate next step in this patient's preventive care?

Show answer & explanation

Answer: Non-contrast chest computed tomography

Answer

The most appropriate next step is non-contrast chest computed tomography to screen for lung cancer.
The correct answer is non-contrast chest computed tomography. The USPSTF recommends annual screening for lung cancer with low-dose computed tomography in adults aged 50 to 80 years who have a ≥\geq 20 pack-year smoking history and currently smoke or have quit within the past 15 years. This 68-year-old patient has a 25 pack-year history and quit 12 years ago, explicitly meeting the criteria for annual screening.

Step-by-Step Solution

1
Evaluate the patient's smoking history and age against current preventive guidelines.
The patient is 68 years old with a 25 pack-year smoking history, having quit 12 years ago.
To determine her eligibility and risk profile for lung cancer screening.
2
Apply the USPSTF lung cancer screening criteria.
She meets all criteria: age between 50 and 80, ≥\geq 20 pack-year history, and has quit within the past 15 years.
Patients meeting these specific parameters require annual screening with low-dose CT.
3
Assess the need for other suggested preventive interventions to rule out distractors.
Cervical, colorectal, and breast cancer screenings are up to date or no longer indicated. Ovarian cancer screening and AAA screening are not recommended.
To verify that no other screening modalities take precedence or are concurrently indicated.

Key Concept

Annual lung cancer screening with low-dose chest computed tomography is recommended for adults aged 50 to 80 years who have a ≥\geq 20 pack-year smoking history and currently smoke or have quit within the past 15 years.
Question 3291Question →

A 48-year-old man presents to the primary care clinic for a routine wellness evaluation. His medical history includes type 2 diabetes mellitus and hypertension, both diagnosed three years ago. His daily medications are metformin and lisinopril. He does not smoke, drinks alcohol occasionally, and denies any illicit drug use. His family history is unremarkable for early-onset cancers. His body mass index is 31 kg/m2kg/m^2. Blood pressure is 128/82 mmHg. His last colonoscopy, performed at age 45, was normal. A hepatitis C virus antibody screening performed three years ago was negative. His immunization records show he received all standard childhood vaccines. In adulthood, he received a tetanus, diphtheria, and pertussis (Tdap) booster four years ago and receives an annual influenza vaccination. He has not received any other vaccines since establishing adult care. Which of the following preventive interventions are indicated for this patient today? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Hepatitis B vaccination; Pneumococcal vaccination

Answer

Hepatitis B vaccination and Pneumococcal vaccination
The correct interventions for this patient are Hepatitis B vaccination and Pneumococcal vaccination. According to the Advisory Committee on Immunization Practices (ACIP), the hepatitis B vaccine series is recommended for all unvaccinated adults aged 19 through 59 years, with particular emphasis on those with diabetes mellitus due to the risk of percutaneous exposure. Furthermore, adults aged 19 through 64 years with certain underlying medical conditions—including diabetes mellitus, chronic heart disease, and chronic lung disease—should receive pneumococcal vaccination (either a single dose of PCV20 or a dose of PCV15 followed by PPSV23).

Step-by-Step Solution

1
Evaluate patient demographics and existing risk factors.
The patient is a 48-year-old non-smoking man with type 2 diabetes mellitus and a BMI of 31 kg/m2kg/m^2.
Age, medical conditions, and lifestyle factors dictate specific preventive screening and vaccination requirements.
2
Assess vaccination history and identify gaps based on comorbidities.
He is up to date on Tdap and influenza vaccines, but lacks adult-specific vaccines indicated for patients with diabetes.
Patients with diabetes mellitus are at higher risk for complications from certain infectious diseases, triggering earlier vaccination indications.
3
Apply the Advisory Committee on Immunization Practices (ACIP) guidelines.
Hepatitis B vaccination is indicated for adults 19-59 with diabetes. Pneumococcal vaccination is indicated for adults 19-64 with diabetes.
These vaccines reduce the risk of hepatitis B exposure (often linked to shared blood glucose monitoring equipment) and severe pneumococcal pneumonia in this vulnerable population.
4
Evaluate the patient's eligibility for additional preventive screenings.
He does not meet the age or risk criteria for prostate cancer screening, lung cancer screening, or the recombinant zoster vaccine.
Applying USPSTF guidelines prevents unnecessary testing and ensures evidence-based, age-appropriate care.

Key Concept

Patients with type 2 diabetes mellitus require specific adult immunizations, including hepatitis B (for adults aged 19-59) and pneumococcal vaccines (for adults aged 19-64), prior to the standard age-based cutoffs.
Question 3292Question →

An occupational health physician is evaluating a corporate executive who requires medical clearance prior to a long-term overseas deployment. The patient is a 50-year-old female whose past medical history is notable for essential hypertension, currently well-managed with daily amlodipine. Her body mass index is 31 kg/m². She reports a previous smoking habit of half a pack of cigarettes per day between the ages of 20 and 45, having ceased all tobacco use five years ago. A comprehensive review of her medical records reveals that she has not undergone any standardized preventive health screenings or diagnostic imaging in the past decade. Which of the following screening modalities are indicated for this patient prior to her departure? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Screening mammography; Hemoglobin A1c measurement; Fecal immunochemical testing

Answer

Screening mammography, Hemoglobin A1c measurement, and Fecal immunochemical testing
Based on current preventive health guidelines, a 50-year-old female with obesity requires screening for breast cancer (mammography), colorectal cancer (fecal immunochemical testing or colonoscopy), and type 2 diabetes (hemoglobin A1c or fasting glucose). Because her medical history shows a 10-year gap in care, all of these routine interventions are currently due.

Step-by-Step Solution

1
Evaluate the patient's age and sex-specific cancer screening requirements.
A 50-year-old female requires breast cancer screening (starting at age 40) and colorectal cancer screening (starting at age 45). Therefore, screening mammography and fecal immunochemical testing are indicated.
Guidelines target broad populations with rising incidences of breast and colon cancer in middle-aged adults.
2
Analyze the patient's metabolic risk factors.
The patient is 50 years old with a BMI of 31 kg/m² (obesity). This combination mandates screening for abnormal blood glucose.
The USPSTF recommends diabetes screening in adults aged 35 to 70 with overweight or obesity to prevent microvascular and macrovascular complications.
3
Calculate the patient's total pack-year smoking history to determine lung cancer screening eligibility.
0.5 packs per day multiplied by 25 years (age 20 to 45) equals 12.5 pack-years. Because this is less than 20 pack-years, lung cancer screening is not indicated.
Low-dose CT is only beneficial when the pre-test probability of lung cancer justifies the radiation and false-positive risks.
4
Assess the patient's risk for osteoporosis.
She is 50 years old without significant risk factors for early bone loss (she has high BMI, which is protective, rather than low body weight).
Routine DEXA scans are deferred until age 65 for women without clinical risk factors.

Key Concept

Appropriate application of age, metabolic, and behavioral risk-factor criteria for adult preventive health screenings.
Question 3293Question →

A 3939-year-old man presents to the addiction medicine clinic complaining of severe muscle aches, abdominal cramping, diarrhea, and rhinorrhea over the past 33 days. He has a history of opioid use disorder and has been stable on a fixed daily dose of oral methadone for the past 22 years without any illicit drug use. Three weeks ago, he was diagnosed with a latent tuberculosis infection after a positive interferon-gamma release assay. He was subsequently started on a daily regimen of oral rifampin, which is planned for a 44-month duration. His vital signs today include a blood pressure of 145/92145/92 mmHg, a heart rate of 110110/min, and a temperature of 37.2∘C37.2^\circ\text{C} (99.0∘F99.0^\circ\text{F}). Physical examination reveals diaphoresis, pupillary dilation, and hyperactive bowel sounds. A urine toxicology screen is negative for all illicit substances. Which of the following is the most appropriate pharmacologic intervention for this patient's current symptoms?

Show answer & explanation

Answer: Increase the daily dose of methadone

Answer

Increase the daily dose of methadone
The correct intervention is to increase the daily dose of methadone. Rifampin is a potent inducer of hepatic cytochrome P450 enzymes (specifically CYP3A4 and CYP2B6), which are heavily involved in the metabolism of methadone. When rifampin is initiated for the treatment of latent or active tuberculosis in a patient maintained on methadone, it significantly accelerates methadone clearance. This leads to subtherapeutic plasma levels and precipitates acute opioid withdrawal (characterized by myalgias, gastrointestinal distress, diaphoresis, and pupillary dilation). The standard clinical management is to monitor the patient and titrate the methadone dose upward (often by 25%25\% to 50%50\%) until withdrawal symptoms resolve.

Step-by-Step Solution

1
Identify the patient's clinical syndrome based on history and physical exam.
The patient exhibits classic signs of acute opioid withdrawal, including diaphoresis, mydriasis, diarrhea, rhinorrhea, and tachycardia.
Recognizing the acute syndrome is necessary to determine if the patient is experiencing drug toxicity, an unrelated infection, or withdrawal.
2
Determine the etiology of the withdrawal syndrome in a previously stable patient.
The recent addition of rifampin, a potent cytochrome P450 (CYP3A4) inducer, has accelerated the hepatic metabolism of methadone.
Understanding the pharmacokinetic interaction between rifampin and methadone explains why subtherapeutic levels have developed despite strict medication adherence.
3
Select the appropriate pharmacologic intervention to resolve the syndrome.
The methadone dose must be increased to overcome the enhanced hepatic clearance.
Restoring therapeutic plasma levels of methadone is the definitive treatment for inducer-precipitated withdrawal.

Key Concept

Drug-drug interactions involving cytochrome P450 induction (e.g., rifampin) can accelerate the metabolism of methadone, necessitating an upward dose titration to prevent or treat opioid withdrawal.
Question 3294Question →

A 64-year-old man is evaluated in the clinic for a routine follow-up. Six months ago, he was diagnosed with highly symptomatic paroxysmal atrial fibrillation and was started on amiodarone for rhythm control. His other medical conditions include hypertension and type 2 diabetes mellitus. His current medications are amiodarone, lisinopril, metformin, and apixaban. He reports feeling well and denies palpitations, shortness of breath, cough, fatigue, heat intolerance, or visual changes. His pulse is 68/min, and blood pressure is 122/78 mmHg. Physical examination, including pulmonary auscultation and neurologic assessment, is unremarkable. An electrocardiogram performed today shows normal sinus rhythm with a heart rate of 66/min and a QTc interval of 440 msec. Baseline chest radiograph, pulmonary function tests, and laboratory studies were normal prior to amiodarone initiation. Which of the following is the most appropriate next step in the monitoring of this patient's pharmacotherapy?

Show answer & explanation

Answer: Obtain serum thyroid-stimulating hormone and hepatic aminotransferase levels

Answer

Obtain serum thyroid-stimulating hormone and hepatic aminotransferase levels
Amiodarone is an iodine-rich class III antiarrhythmic agent associated with significant long-term, multi-organ toxicity, primarily affecting the thyroid, liver, and lungs. Because of its large volume of distribution, long half-life, and tissue accumulation, structured longitudinal surveillance is mandatory. Guidelines recommend obtaining a baseline thyroid-stimulating hormone (TSH), free T4, and hepatic panel, followed by repeat testing every 6 months. Therefore, checking TSH and hepatic aminotransferase levels is the correct monitoring step for this asymptomatic patient at his 6-month follow-up visit. Additionally, an electrocardiogram should be performed every 3 to 6 months to monitor for QTc prolongation and bradycardia, which was appropriately completed during this visit.

Step-by-Step Solution

1
Identify the primary intervention requiring monitoring.
The patient is on chronic amiodarone therapy for atrial fibrillation rhythm control.
Amiodarone is a high-risk medication with a known profile of substantial long-term toxicities, requiring a structured surveillance protocol.
2
Determine the time elapsed since initiation and current symptoms.
It has been 6 months since initiation, and the patient is completely asymptomatic.
The timing dictates which surveillance tests are due. At 6 months, specific end-organ laboratory monitoring is universally recommended regardless of symptoms.
3
Apply guideline-based monitoring recommendations for amiodarone at the 6-month mark.
Guidelines recommend checking thyroid-stimulating hormone (TSH), free T4, and liver aminotransferases every 6 months.
Amiodarone can cause hypo- or hyperthyroidism and hepatotoxicity. Routine testing detects subclinical organ dysfunction before severe toxicity develops.

Key Concept

Patients receiving chronic amiodarone therapy require routine monitoring of hepatic aminotransferases and thyroid function tests (TSH) every 6 months to detect asymptomatic end-organ toxicity.
Estimated Time:1m 0s
Question 3295Question →

A 48-year-old man is brought to the emergency department via ambulance due to a prolonged seizure. His wife reports that he abruptly lost consciousness and began experiencing generalized shaking while eating breakfast. The paramedics arrived 10 minutes after the onset of the episode and noted continuous, generalized tonic-clonic motor activity. En route to the hospital, his convulsions did not cease. On arrival in the emergency bay, the patient remains unresponsive with active generalized tonic-clonic movements. His estimated weight is 80 kg (176 lb). Vital signs show a blood pressure of 168/94 mmHg, heart rate of 136/min, and oxygen saturation of 92% on a non-rebreather mask. Point-of-care blood glucose is 102 mg/dL. He has no established intravenous access.

Arrange the following pharmacologic interventions in the correct sequential order for the evidence-based management of this patient's emergency, from the immediate initial step to the therapy reserved for super-refractory disease.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence for managing status epilepticus in this scenario is: 1) Administer intramuscular midazolam, 2) Establish intravenous access and administer intravenous fosphenytoin, 3) Perform endotracheal intubation and initiate a continuous propofol infusion, 4) Initiate a continuous pentobarbital infusion with continuous electroencephalogram monitoring.
The management of status epilepticus follows a strict, time-dependent treatment algorithm. In the initial stabilization phase (0-5 minutes), administering a first-line benzodiazepine is critical. Because this patient lacks IV access, intramuscular (IM) midazolam is the evidence-based first choice; attempting IV access during active convulsions delays life-saving therapy. Once the initial abortive agent is given, IV access is established to administer a second-line non-benzodiazepine antiseizure medication (e.g., IV fosphenytoin, valproate, or levetiracetam) at the 20-minute mark to treat established status. If clinical or electrographic seizures persist beyond 40 minutes despite these interventions, the patient has entered refractory status epilepticus. This condition requires endotracheal intubation for airway protection and the initiation of a continuous anesthetic infusion, such as propofol or midazolam. Finally, if the patient continues to seize despite a continuous anesthetic infusion for over 24 hours (super-refractory status epilepticus), the intervention of last resort is inducing a deep barbiturate coma (e.g., pentobarbital or thiopental infusion) guided by continuous electroencephalogram (EEG) monitoring to achieve burst suppression.

Step-by-Step Solution

1
Identify the clinical emergency and assess logistical constraints.
The patient is in generalized convulsive status epilepticus (seizure duration >5 minutes) and currently lacks intravenous access.
Immediate pharmacologic termination of the seizure is required to prevent irreversible neuronal injury, but the route of administration is dictated by the lack of an IV line.
2
Select the appropriate first-line abortive agent.
Intramuscular midazolam is chosen as the initial intervention.
Current guidelines strictly recommend IM midazolam as the first-line agent when IV access is not immediately available, as it has rapid absorption and avoids the delay of attempting IV placement in a convulsing patient.
3
Determine the necessary second-line maintenance therapy.
Intravenous fosphenytoin is administered once IV access is secured.
A long-acting, non-benzodiazepine antiseizure medication is required at the 20-minute mark to treat established status epilepticus and prevent seizure recurrence.
4
Plan for the management of refractory status epilepticus.
Endotracheal intubation and a continuous propofol infusion are prioritized next.
Failure of first- and second-line agents defines refractory status, which necessitates mechanical ventilation and continuous general anesthesia to suppress cortical activity.
5
Plan for the management of super-refractory status epilepticus.
Continuous pentobarbital infusion guided by EEG is the final step.
Failure of a continuous anesthetic infusion requires escalation to a deep barbiturate coma with burst suppression monitoring, which is the therapy of last resort due to high morbidity.

Key Concept

The protocolized, sequential escalation of pharmacotherapy in status epilepticus based on time elapsed and response to prior treatments.
Question 3296Question →

A 62-year-old man presents to the clinic for a routine health maintenance visit. His medical history is significant for type 2 diabetes mellitus and stage 3a chronic kidney disease. He smoked one pack of cigarettes daily from age 20 to 50, but quit 12 years ago. He is currently asymptomatic and reports good medication adherence.

His preventive care history includes the following:
- Colonoscopy at age 55 revealed no polyps or abnormalities.
- Recombinant zoster vaccine series was completed at age 55.
- Tetanus, diphtheria, and acellular pertussis (Tdap) booster was administered 5 years ago.
- Annual influenza and updated COVID-19 vaccines were administered last month.
- One-time hepatitis C antibody screening was negative 3 years ago.
- He has never received any pneumococcal vaccinations.

Physical examination is unremarkable. Which of the following preventive interventions are currently indicated for this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Annual low-dose computed tomography of the chest; Administration of a pneumococcal conjugate vaccine

Answer

Annual low-dose computed tomography of the chest AND Administration of a pneumococcal conjugate vaccine
Annual low-dose computed tomography (LDCT) of the chest is indicated because the patient meets the criteria of being aged 50 to 80 years, having at least a 20 pack-year smoking history (he has 30 pack-years), and having quit within the past 15 years (he quit 12 years ago). Administration of a pneumococcal conjugate vaccine is also indicated because adults aged 19 to 64 years with certain underlying medical conditions, such as diabetes mellitus and chronic kidney disease, require pneumococcal vaccination.

Step-by-Step Solution

1
Evaluate the patient's smoking history and age for lung cancer screening.
The patient is 62 years old with a 30 pack-year history, having quit 12 years ago.
Guidelines recommend annual LDCT for ages 50 to 80 with 20 or more pack-years who currently smoke or quit within the last 15 years.
2
Assess the patient's indication for pneumococcal vaccination.
The patient has type 2 diabetes mellitus and chronic kidney disease.
Adults aged 19 to 64 with these comorbidities are at higher risk and require pneumococcal vaccination.
3
Determine if the patient meets criteria for abdominal aortic aneurysm screening.
The patient is a male former smoker but is only 62 years old.
AAA screening is recommended beginning at age 65 for men who have ever smoked.
4
Check colorectal cancer screening status.
The patient had a normal colonoscopy at age 55.
The next screening is due in 10 years (at age 65). Interval non-invasive testing is not indicated.
5
Evaluate the indication for aspirin for primary prevention.
The patient is 62 years old.
Aspirin is no longer recommended for primary prevention of cardiovascular disease in adults aged 60 and older.

Key Concept

Application of age- and risk-based preventive screening and immunization guidelines in the ambulatory setting.
Question 3297Question →

A 28-year-old man with type 1 diabetes mellitus is receiving care in the intensive care unit for severe diabetic ketoacidosis. He is currently being managed with intravenous fluid resuscitation and a continuous intravenous regular insulin infusion. Arrange the following clinical milestones and monitoring-based interventions in the correct chronological sequence required for a safe transition to maintenance subcutaneous therapy.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with monitoring blood glucose until it reaches 200 mg/dL, immediately adding dextrose to the IV fluids, continuing to monitor until the anion gap closes, administering subcutaneous insulin, and finally discontinuing the IV insulin infusion two hours later.
The standard protocol for managing diabetic ketoacidosis (DKA) requires rigorous sequential monitoring and treatment modification. Initially, IV fluids and an insulin infusion are started. Because glucose normalizes faster than the ketoacidosis resolves, when the blood glucose falls to 200 mg/dL, 5% dextrose must be added to the IV fluids. This prevents hypoglycemia and allows the insulin infusion to continue suppressing lipolysis and ketogenesis. The physician must then monitor serial basic metabolic panels until the anion gap closes (≤ 12 mEq/L), which signals the resolution of DKA. Once resolved, the transition to subcutaneous insulin is initiated by administering a long-acting basal dose. Finally, because subcutaneous insulin takes 1 to 2 hours to achieve therapeutic systemic absorption, the IV insulin infusion must be maintained for an overlapping 2-hour period before being discontinued to prevent a relapse of DKA.

Step-by-Step Solution

1
Monitor capillary blood glucose hourly until it reaches the 200 mg/dL threshold.
Identifies the point where the patient is at risk for hypoglycemia if pure saline is continued.
Blood glucose typically normalizes much faster than the metabolic acidosis resolves.
2
Add 5% dextrose to the intravenous fluid regimen.
Maintains blood glucose levels in a safe range (150-200 mg/dL).
Allows the continuous insulin infusion to be maintained at a rate sufficient to clear ketones without inducing iatrogenic hypoglycemia.
3
Monitor serial chemistry panels every 2 to 4 hours to assess the anion gap.
Confirms the closure of the anion gap (typically ≤ 12 mEq/L) and normalization of bicarbonate.
Closure of the anion gap is the definitive marker that diabetic ketoacidosis has resolved and continuous IV insulin is no longer strictly required for ketone suppression.
4
Administer the first dose of subcutaneous basal insulin.
Begins the transition to long-term maintenance therapy.
Subcutaneous insulin must be given once the acidosis is resolved and the patient is preparing to resume an oral diet.
5
Maintain the IV insulin infusion for an additional 2 hours before discontinuing it.
Provides an insulin overlap.
Subcutaneous insulin has a delayed onset of action. The overlap prevents a window of insulin deficiency and subsequent rebound ketoacidosis.

Key Concept

Monitoring and Sequencing the Transition off Intravenous Insulin in Diabetic Ketoacidosis
Question 3298Question →

During a scheduled annual wellness examination, a 60-year-old woman is evaluated in the primary care clinic. She feels well and has no acute complaints. Her medical history is notable for seropositive rheumatoid arthritis, which has been well-controlled on a stable regimen of adalimumab and methotrexate for the past four years. She has a 10 pack-year smoking history, currently smoking half a pack of cigarettes daily. Her family history is significant for her mother being diagnosed with breast cancer at age 72 and her father having a stroke at age 80.

Review of her preventive health record reveals the following:
- Screening colonoscopy at age 52 was normal.
- Screening mammography 6 months ago was normal.
- Pap smear with human papillomavirus (HPV) co-testing 2 years ago was normal.
- Hepatitis C virus antibody test 1 year ago was negative.

Her immunizations are up to date, including a 20-valent pneumococcal conjugate vaccine (PCV20) at age 58, two doses of the recombinant zoster vaccine at age 50, and an inactivated influenza vaccine 3 weeks ago.

Her body mass index is 21 kg/m². Physical examination shows no joint effusions, tenderness, or deformities.

Which of the following is the most appropriate next step in preventive care for this patient?

Show answer & explanation

Answer: Dual-energy x-ray absorptiometry

Answer

The most appropriate next step is performing dual-energy x-ray absorptiometry (DEXA) to screen for osteoporosis.
The correct answer is dual-energy x-ray absorptiometry (DEXA). The United States Preventive Services Task Force (USPSTF) recommends screening for osteoporosis with bone measurement testing (e.g., DEXA scan) in women 65 years and older, as well as in postmenopausal women younger than 65 years who are at increased risk of osteoporosis. Increased risk is defined as having a 10-year risk of a major osteoporotic fracture equal to or greater than that of a 65-year-old white woman with no additional risk factors (which is approximately 8.4% using the FRAX tool). This patient has multiple significant clinical risk factors for osteoporosis, including a diagnosis of rheumatoid arthritis, current tobacco use, and a low-normal body mass index (21 kg/m²). These factors place her well above the risk threshold, making a DEXA scan the most appropriate and indicated next step in her preventive care.

Step-by-Step Solution

1
Analyze the patient's demographics, past medical history, and social history.
The patient is a 60-year-old postmenopausal woman with rheumatoid arthritis, active tobacco use (10 pack-years), and a BMI of 21 kg/m².
Identifying these clinical factors is necessary to calculate patient-specific risks for various diseases targeted by screening guidelines.
2
Evaluate the status of her routine cancer and infectious disease screenings based on the provided dates.
Colorectal cancer (colonoscopy 8 years ago), breast cancer (mammogram 6 months ago), cervical cancer (Pap/HPV 2 years ago), and HCV screenings are all up to date. She is also fully vaccinated for her age and risk profile.
This eliminates several options by confirming that these specific screenings and vaccines are not currently due.
3
Assess her eligibility for specialized screenings based on her unique risk factors.
While she does not meet the 20 pack-year requirement for lung cancer screening (LDCT) and AAA screening is not routinely indicated for women, her rheumatoid arthritis and smoking status significantly increase her osteoporosis risk.
The USPSTF recommends bone density screening for women under 65 if their 10-year fracture risk meets or exceeds 8.4%. Her secondary causes of osteoporosis (RA) and lifestyle factors exceed this threshold.

Key Concept

The United States Preventive Services Task Force (USPSTF) recommends screening for osteoporosis with bone measurement testing in postmenopausal women younger than 65 years who are at increased risk of osteoporosis (10-year fracture risk ≥8.4%).
Question 3299Question →

Match each clinical scenario evaluated in the primary care setting with the most appropriate, evidence-based preventive care intervention.

Click a left item, then click its matching right item

Items

A 41-year-old female with no significant past medical history or family history of malignancy.
A 54-year-old male with a 25 pack-year smoking history who successfully quit smoking 10 years ago.
A 66-year-old male with essential hypertension who reports having smoked approximately 200 cigarettes total in his early twenties.
A 31-year-old female at 29 weeks gestation who received a tetanus booster 3 years ago following a minor laceration.

Matches

Show answer & explanation

Answer

The 41-year-old female requires screening mammography. The 54-year-old former smoker requires annual LDCT of the chest. The 66-year-old male who previously smoked requires a one-time abdominal aortic ultrasound. The 31-year-old pregnant female requires Tdap vaccination.
Each patient meets specific age and risk factor thresholds established by current USPSTF and ACIP guidelines for preventive screening and vaccination. The 41-year-old female meets the updated age threshold of 40 for starting mammography. The 54-year-old male fits the 50-80 age range, >20 pack-year history, and <15 years since quitting criteria for LDCT. The 66-year-old male meets the 65-75 age range and >100 lifetime cigarette exposure criteria for AAA screening. The 31-year-old pregnant female is within the 27-36 week gestation window requiring Tdap vaccination.

Step-by-Step Solution

1
Evaluate the 41-year-old female for cancer screening eligibility.
She is eligible for breast cancer screening.
Current USPSTF guidelines recommend starting biennial screening mammography at age 40 for average-risk women, rather than waiting until age 50.
2
Assess the 54-year-old male's smoking history for lung cancer screening.
He meets criteria for low-dose computed tomography (LDCT).
He falls within the 50-80 age range, has greater than a 20 pack-year smoking history, and his quit date is within the last 15 years.
3
Determine vascular screening needs for the 66-year-old male.
He requires an abdominal aortic aneurysm (AAA) screening.
He is a male aged 65-75 with a history of smoking. A lifetime exposure of at least 100 cigarettes qualifies a patient as an 'ever smoker' for AAA screening purposes.
4
Review the immunization requirements for the 31-year-old pregnant female.
She requires the Tdap vaccine.
Tdap is indicated in every pregnancy between 27 and 36 weeks of gestation to provide passive immunity to the infant, regardless of when her last tetanus booster was administered.

Key Concept

Application of age- and risk-appropriate preventive screening and immunization guidelines
Question 3300Question →

A 38-year-old man is evaluated in the hospital on day 4 of admission for an acute left lower extremity deep vein thrombosis. He has a known history of primary antiphospholipid syndrome. Upon admission, he was started on a continuous intravenous unfractionated heparin infusion and oral warfarin.

Daily INR values since admission are as follows:

Hospital DayINR Result
Day 11.1
Day 21.2
Day 31.7
Day 4 (today)2.4

Today's laboratory results show an activated partial thromboplastin time (aPTT) of 68 seconds (therapeutic goal: 60-80 seconds). His platelet count is 210,000/mm³ (baseline 225,000/mm³ on admission). The patient reports that his leg swelling has significantly improved, though he still experiences mild residual leg pain. He has no signs of clinical bleeding.

Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

Show answer & explanation

Answer: Continue both the unfractionated heparin infusion and oral warfarin

Answer

Continue both the unfractionated heparin infusion and oral warfarin
The most appropriate next step in management is to continue both the unfractionated heparin infusion and oral warfarin. When initiating a vitamin K antagonist (warfarin) for the treatment of an acute deep vein thrombosis, patients must receive concurrent bridging therapy with a rapid-acting parenteral anticoagulant. This overlap must be maintained for a strict minimum of 5 days AND until the INR is in the therapeutic range (typically 2.0-3.0) for at least 24 hours. Because the patient is only on day 4 of admission and his INR just entered the therapeutic range today (it was 1.7 yesterday), neither of the required safety thresholds has been fulfilled. Therefore, both medications must be continued to prevent a transient hypercoagulable state.

Step-by-Step Solution

1
Evaluate the current duration of the parenteral and oral anticoagulant overlap.
The patient has been on combined unfractionated heparin and warfarin therapy for exactly 4 days.
Current standard-of-care guidelines mandate a minimum of 5 days of overlap for safe warfarin initiation.
2
Analyze the patient's current INR in the context of therapeutic goals and timeline requirements.
The INR reached the therapeutic range (2.4) for the first time today; yesterday it was subtherapeutic (1.7).
Heparin can only be discontinued safely when the INR has been therapeutic (2.0 or greater) for a minimum of 24 consecutive hours.
3
Synthesize the duration and laboratory parameters to determine the immediate management step.
Unfractionated heparin must be continued concurrently with warfarin.
Neither the minimum 5-day duration rule nor the 24-hour therapeutic INR requirement has been satisfied.

Key Concept

For the treatment of venous thromboembolism, bridging therapy with a parenteral anticoagulant (such as unfractionated heparin) and warfarin must be continued concurrently for a minimum of 5 days AND until the INR is therapeutic (2.0 or greater) for at least 24 hours.
PreviousPage 165 / 237Next